In the setting of NAFLD, PPARα is activated by higher intrahepatic fatty acids [24] and sustained activation of this dysfunctional PPARα signaling pathway results in the elevated FGF21 levels that are characteristic of individuals with NAFLD [25]. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.